Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10290881 | 0.87 | TAAR1 (0.47) | TAAR1CA12CA1CA2CA7 | |
| SCHEMBL11983792 | 0.85 | ALDH1A1 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13913528 | 0.82 | PDE3B (0.35) | ALDH1A1CYP1A2MAOACYP3A4MAOB | |
| SCHEMBL20226996 | 0.80 | ACHE (0.45) | ALDH1A1CYP3A4 | |
| SCHEMBL19658032 | 0.80 | TAAR1 (0.41) | TAAR1ALDH1A1CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL13748180 | 0.80 | TAAR1 (0.41) | TAAR1ALDH1A1CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL20375023 | 0.80 | TAAR1 (0.41) | TAAR1ALDH1A1CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL20226999 | 0.78 | PDE3B (0.37) | — | |
| SCHEMBL27733385 | 0.78 | ERN1 (0.36) | — | |
| SCHEMBL16018014 | 0.78 | CYP3A4 (0.47) | TAAR1CA1CA2ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | CONOPCO, INC., D/B/A UNILEVER (US) | 2016-01-07 | — | — | US | disclosed |
| US-20140256830-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER N.V. (NL) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | NQO1, RBP4, KEAP1 | TAAR1 4655/4885CA12 4722/4885CA1 4880/4885 |
| US-20140256830-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | NQO1, RBP4, KEAP1 | TAAR1 4655/4885CA12 4722/4885CA1 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.